NCT03538704 (ECFerSp) is a NA clinical trial of Metformin in Endometrial Cancer, sponsored by Peking University People's Hospital.

Who is sponsoring NCT03538704?

NCT03538704 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT03538704?

Interventions in NCT03538704: Metformin.

What condition does NCT03538704 study?

NCT03538704 studies Endometrial Cancer, Fertility.

Is NCT03538704 still recruiting?

NCT03538704 is currently status unknown. Last updated 29 May 2018.

Last reviewed 2018-05-29 · How we verify

NCT03538704: ECFerSp

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Fertility-sparing Therapy of Early Endometrial Cancer

Status unknown NA Last updated 29 May 2018

What this trial tests

NA trial testing Metformin in Endometrial Cancer in 80 participants. Status unknown.

Timeline

1 January 2015

Primary endpoint
31 March 2020

31 December 2020

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 January 2015
Primary completion	31 March 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →
Fertility — all drugs for Fertility →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 40, female only, with Endometrial Cancer or Fertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effect of Fertility-sparing Therapy of Early Endometrial Cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Fertility-sparing treatment in early endometrial cancer: current state and future strategies.
Obermair A, Baxter E, Brennan DJ, McAlpine JN, et al · · 2020 · cited 62× · PMID 32689770 · DOI 10.5468/ogs.19169
Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.
Tanos P, Dimitriou S, Gullo G, Tanos V. · · 2022 · cited 46× · PMID 35269800 · DOI 10.3390/ijms23052653
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A, Kawasaki Y, Hori M, Fujiwara T, et al · · 2020 · cited 27× · PMID 32114477 · DOI 10.1136/bmjopen-2019-035416
The Perspectives of Fertility Preservation in Women with Endometrial Cancer.
Knez J, Al Mahdawi L, Takač I, Sobočan M. · · 2021 · cited 22× · PMID 33546293 · DOI 10.3390/cancers13040602
Improving response to progestin treatment of low-grade endometrial cancer.
Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, et al · · 2020 · cited 22× · PMID 32381512 · DOI 10.1136/ijgc-2020-001309
Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience.
Wang Y, Yang JX. · · 2018 · cited 21× · PMID 30584372 · DOI 10.2147/cmar.s188087
Molecular Prognosticators Guiding Fertility-Sparing Surgery in Early-Stage Endometrial Cancer: A Comprehensive Review.
Shaikh S, Haque S, Khalifey HT, Samour HA, et al · · 2025 · PMID 41300969 · DOI 10.3390/cancers17223602

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03538704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 29 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03538704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing